RNA-based therapeutics, including siRNA, mRNA, and ASO, are rapidly transforming precision medicine, offering promising treatments for cancer, genetic disorders, infectious diseases, and vaccines. However, challenges such as RNA instability, susceptibility to degradation, and poor cellular uptake hinder their clinical translation.
As a global leader in lipid-based drug delivery technologies, Litchlab is revolutionizing RNA delivery with its advanced liposomal platforms. Our cutting-edge solutions enhance RNA stability, targeting precision, and bioavailability, helping to bridge the gap between research and clinical application.
How Do Liposomes Enhance RNA Drug Delivery?
Litchlab’s intelligent liposomal technology integrates chemical modifications, nanotechnology, and bioengineering to overcome key biological barriers and ensure efficient RNA delivery. Key mechanisms include:
Protecting RNA from Degradation
RNA molecules are highly susceptible to nuclease degradation. Litchlab’s lipid-based nanocarriers encapsulate RNA to shield it from enzymatic breakdown, significantly prolonging circulation time.
Enhancing Cellular Uptake
Naked RNA molecules struggle to cross cell membranes. Litchlab’s engineered liposomes optimize charge, particle size, and lipid composition, enhancing cellular uptake and facilitating efficient intracellular RNA delivery.
Targeted Delivery, Reduced Toxicity
Litchlab employs precision lipid surface modifications such as PEGylation, ligand conjugation, and antibody attachment to enable organ- and cell-specific targeting, minimizing off-target effects and improving therapeutic efficacy.
Smart Release for Maximum Therapeutic Impact
Utilizing pH-sensitive, enzyme-responsive, and thermosensitive release mechanisms, Litchlab’s liposomes ensure controlled and sustained RNA release within target cells, optimizing therapeutic outcomes.
Litchlab’s RNA Drug Delivery Platforms
siRNA Delivery: Effective Gene Silencing
Litchlab’s cationic liposomes (cLNPs) and lipid nanoparticles (LNPs) efficiently encapsulate siRNA, facilitating its intracellular transport and gene silencing.
Cancer Therapy: Silencing oncogenes such as KRAS, MYC
Antiviral Treatments: Targeting viral RNA in diseases like HBV, HIV
Genetic Disorders: Silencing mutated genes in rare diseases
mRNA Delivery: Vaccines & Protein Replacement
Litchlab’s ionizable lipid nanoparticles (LNPs) provide an optimal platform for mRNA-based vaccines and therapeutic protein expression, ensuring safe and efficient delivery.
mRNA Vaccines: COVID-19, cancer immunotherapy, autoimmune disease vaccines
Protein Replacement Therapy: Treating congenital deficiencies like hemophilia, cystic fibrosis
Personalized Gene Therapy: CAR-T cell therapy, tumor-targeting mRNA
ASO & RNA Editing: Expanding the Frontier of Genetic Medicine
Litchlab’s lipid-based carriers optimize antisense oligonucleotide (ASO) and CRISPR-Cas9 RNA delivery, advancing gene correction therapies.
ASO Therapy: Treating Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA)
CRISPR-Cas9 RNA Delivery: Enabling precise gene editing for inherited diseases
Why Choose Litchlab?
Advanced Lipid Synthesis & GMP-Grade Manufacturing
Proprietary synthesis of PEGylated lipids, cationic lipids, and ionizable lipids for enhanced drug delivery
GMP-compliant production, supporting both clinical and commercial applications
Custom RNA-Lipid Formulation Development
Tailored optimization of lipid composition, charge distribution, and particle size for maximum delivery efficiency
Comprehensive formulation screening, stability testing, and pharmacokinetic (PK) optimization
Clinical & Regulatory Support
End-to-end services including in vitro & in vivo analysis, CMC development, and clinical trial support
Litchlab: Driving the Future of RNA Therapeutics
RNA-based drugs are at the forefront of modern medicine. Litchlab’s expertise in liposomal engineering, RNA delivery optimization, GMP-grade production, and AI-assisted formulation development positions it as a premier partner for pharmaceutical and biotech companies.
From siRNA gene silencing and mRNA vaccines to RNA editing, Litchlab is accelerating the development of next-generation RNA therapies—advancing clinical applications and transforming patient care.
For more information, please feel free to contact us at:
E-Mail:RD2@Litchlab.com
